10x Genomics, Inc. Form 8-K Summary
Business context and reporting period
10x Genomics, Inc. filed a Current Report on Form 8-K dated November 7, 2019. The filing reports the issuance of a press release announcing financial results for the quarter ended September 30, 2019. The company’s Class A common stock trades on Nasdaq under the symbol TXG.
Financial results and liquidity
The filing itself does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, or other financial metrics. These details were included in Exhibit 99.1, the referenced press release, which is not included in the provided filing text.
Material changes versus the prior comparable period
The provided filing text does not state the company’s year-over-year or sequential changes in financial results.
Guidance, outlook, risks, and unusual items
- No guidance, outlook, management commentary, risk disclosures, contingencies, or unusual items are described in the provided text.
- The financial information was furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Securities Exchange Act, nor incorporated by reference into other filings unless specifically stated.
- The company identified itself as an emerging growth company.
Important facts for investors to verify
- Review Exhibit 99.1 for the complete quarterly financial results and management commentary.
- Verify revenue, operating expenses, net loss, cash flow, cash and investments, debt, and liquidity metrics for the quarter ended September 30, 2019.
- Compare the reported results with the prior-year and preceding-quarter periods.
- Review any guidance, non-GAAP measures, business updates, and risk factors contained in the press release.